GlassScriptPhysician profile
Caleb Edward Kroll
NPI 1205921780
$4,631.69
in general payments reported to CMS, 2019-2025
35 companies · $883 in 2025
The $883 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2020: $708 · 2021: $639 · 2022: $577 · 2023: $534 · 2024: $421 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,837.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $740.50 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept |
| Nevro Corp. | $646.52 | 2020-2024 | Senza |
| Collegium Pharmaceutical, INC. | $627.02 | 2019-2025 | Xtampza, Belbuca |
| Abbott Laboratories | $596.77 | 2019-2025 | Eterna, Proclaim, Octrode |
| Medtronic USA, INC. | $330.76 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $264.69 | 2019-2022 | |
| Medtronic, INC. | $213.83 | 2022-2025 | Inceptiv, Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Biodelivery Sciences International, INC. | $107.97 | 2019-2020 | |
| Biotronik Nro, INC. | $98.48 | 2024-2025 | Prospera |
| Pacira Pharmaceuticals Incorporated | $87.38 | 2023-2025 | Iovera, Zilretta, Exparel |
| Fidia Pharma USA INC. | $74.75 | 2019-2022 | |
| Si-Bone, INC. | $72.69 | 2019-2024 | |
| Tersera Therapeutics LLC | $67.44 | 2019-2025 | Prialt |
| Abbvie INC. | $59.86 | 2023-2025 | |
| Allergan, INC. | $55.04 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $54.51 | 2025 | Senza |
| Vertos Medical, INC. | $52.25 | 2023 | Mild Device Kit |
| Pfizer INC. | $50.12 | 2019 | |
| Arbor Pharmaceuticals, INC. | $49.08 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.37 | 2019-2023 | Relistor |
| Lilly USA, LLC | $42.76 | 2019 | |
| Stimwave Technologies Incorporated | $42.62 | 2020-2022 | |
| Pacira Therapeutics, INC. | $39.33 | 2019 | |
| Assertio Therapeutics, INC. | $32.71 | 2019 | |
| Ibsa Pharma INC. | $22.17 | 2022 | |
| Spr Therapeutics, INC | $20.92 | 2025 | Sprint Pns System |
| Novartis Pharmaceuticals Corporation | $19.71 | 2019 | |
| Bioventus LLC | $18.93 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.92 | 2023 | Horizant |
| Depuy Synthes Sales INC. | $15.93 | 2019 | |
| Tonix Medicines, INC. | $15.69 | 2025 | Tonmya |
| Vertex Pharmaceuticals Incorporated | $14.37 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.22 | 2022 | |
| Zimmer Biomet Holdings, INC. | $11.76 | 2020 | |
| Electronic Waveform Lab, INC. | $11.62 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Kroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.